Index

Note: Page numbers of article titles are in **boldface** type.

A

Acarbose, for prevention, 362, 380
Actos Now for the Prevention of Diabetes Trial, 388
Adipokines, cardiovascular disease and, 313
American Diabetes Association
diagnostic criteria of, 290–293, 301
treatment recommendations of, 390–391
Angiotensin-converting enzyme inhibitors, for prevention, 363
Antihypertensive drugs, for prevention, 363
Atherosclerosis
endothelial dysfunction and, 311–312
in dyslipidemia, 313–314
in pediatric patients, 410–411
Australian Diabetes, Obesity and Lifestyle study, 349
Australian Diabetes Society, treatment guidelines of, 390–391
Australian Type 2 Diabetes Risk Assessment Tool, 304
Autonomic neuropathy, 317–318

B

Bariatric surgery, for prevention, 364, 389
Bedford study, of prevention, 359
Beta-cell dysfunction, 332–335

C

Canadian Normoglycemia Outcomes Evaluation (CANOE) study, 361, 363, 388
Cardiovascular disease, **309–325**
in pediatric patients, 410–412
macrovascular, 310–316
IFG versus IGT, 310
linked to hyperglycemia, 314–316
not mediated by hyperglycemia, 310–314
pathogenesis of, 310
microvascular, 316–318
prevention of, 364
risk of
glycated hemoglobin A₁c and, 303
in IFG, 344–345
in IGT, 302, 344–345
Cost considerations. See Economics.
C-reactive protein, cardiovascular disease and, 313
Cytokines, cardiovascular disease and, 313, 315

D
Da Qing Study, 355–356, 358, 364–366, 388
DECODA (Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Asia) study, 300–301
DECODE (Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe) study, 300–301
DESIR (Epidemiologic Study on the Insulin Resistance Syndrome) study, 301
DETECT-2 study, of epidemiology, 301
Diabetes Atlas, prevalence data in, 299–300
Diabetes Control and Complications Trial, 354
Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Asia (DECODA) study, 300–301
Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe (DECODE) study, 300–301
Diabetes in Europe-Prevention using Lifestyle, Physical Activity and Nutritional Intervention project, 398
Diabetes mellitus
costs of, 374–376
definition of, 289–293
diagnostic criteria for, 289–293
prevention of
economics of, 367–368, 373–384, 389
effectiveness of, 354–359
evidence for, 398
four-level model for, 402–404
in pediatric patients, 414
intervention manager training for, 398–399
lifestyle interventions for, 366–367, 387–388
mechanism of action of, 367
national policy on, 402
network for, 405
outcomes of, 364–366
pharmacologic agents for, 359–364, 366–367
practical guidance for, 404
programs for, 353–372
public health implications of, 397–407
quality indicators for, 399
recommendations for, 389–392
sustainable effects of, 364–366
target population for, 399, 402
toolkit for, 404–405
Diabetes Prevention Program, 357–358, 360, 362, 365, 378–379
Diabetes Prevention Study, 356
Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study, 361, 363, 379, 381, 388
Diabetes risk scores, 347–349
Dyslipidemia, cardiovascular disease and, 313–314

E
Economics, of diabetes prevention, 367–368, 373–384, 389
  cost utility, 378–381
  cost-effectiveness analysis, 377–378, 389
  costs, 374–376
  quality of life and, 376–377
Endocrine Society, prediabetes treatment guidelines of, 391
Endothelial dysfunction, 311–312, 315
Epidemiologic Study on the Insulin Resistance Syndrome (DESIR) study, 301
Epidemiology of Diabetes Interventions and Complications study, 354
Epigenetic modification, in vasculopathy, 316
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, glucose
  intolerance definition of, 289–292
Eye disorders, 317

F
Fasting plasma glucose, in diagnostic criteria, 290–292, 294
Fibrinolysis, impaired, cardiovascular disease and, 314
Finnish Diabetes Risk Score, 304, 348
FPG (fasting plasma glucose), in diagnostic criteria, 290–292

G
Glucagon, elevated, 329–330
Gluconeogenesis, 328–330
Glucose
  disposal of, 330–332
  elevated. See Hyperglycemia; Impaired fasting glucose; Impaired glucose tolerance.
  endogenous production of, 328–330
  release of, 328–330
Glucose intolerance, definition of, 289–290
Glycated hemoglobin A1c
  in diagnostic criteria, 292–293, 302–303, 347
  natural history of, 303
Glycogenolysis, 328–330

H
Heart Outcomes Prevention Evaluation (HOPE) study, 363
Hemoglobin A1c, glycated. See Glycated hemoglobin A1c.
Hoom Study, 355
Hyperglycemia. See also Impaired fasting glucose; Impaired glucose tolerance.
  cardiovascular disease in, 314–316
  postchallenge, 314–315
Hyperinsulinemia
  cardiovascular disease in, 310–311
  in metabolic syndrome, 412–414
I

IFG. See Impaired fasting glucose.
IGT. See Impaired glucose tolerance.

IMAGE (Development and Implementation of a European Guideline and Training Standards of Diabetes Prevention) project, 398–399, 404–405

Impaired fasting glucose
  as predictor of diabetes, 343–344
  cardiovascular disease risk in, 301, 310, 344–345
  definition of, 293–294
  diagnostic cut point for, 344–346
  epidemiology of, 299–302
  in diagnostic criteria, 290–292, 342–347
  natural history of, 301
  pathogenesis of, 328–329, 335–336
  prevention of, 373–384

Impaired glucose tolerance
  as predictor of diabetes, 343–344
  cardiovascular disease risk in, 302, 310, 344–345
  definition of, 293–294
  diagnostic cut point for, 344–346
  epidemiology of, 299–302
  in diagnostic criteria, 290–291, 342–347
  natural history of, 301
  pathogenesis of, glucose release, 328–329
  prevention of, economics of, 373–384
  test for, reproducibility of, 302

Indian Diabetes Prevention Program, 357–360, 362–363, 388
Indian Health Services guidelines, for prediabetes treatment, 390

Inflammation, cardiovascular disease and
  in obesity, 312–313
  thrombosis, 315–316

Insulin resistance, 330–335
  cardiovascular disease in, 310–311
  in metabolic syndrome, 412–414

Insulin sensitivity, 330–332

Interleukin-6, cardiovascular disease and, 313

J

Japanese Diabetes Prevention Study, for prevention, 357, 359

K

Kidney, dysfunction of, 316–317

L

Leptin, cardiovascular disease and, 313
Lipoprotein profile, cardiovascular disease and, 313–314
M
Malmö feasibility study, for prevention, 355, 365–366
Meglitinide, for prevention, 363–364
Metabolic syndrome, in pediatric patients, 412–414
Metformin, for prevention, 362, 366–367, 380, 388

N
Nateglinide, for prevention, 363–364
NAteglinide and Valsartan Improved Glucose Tolerance Outcomes Research
(NAVIGATOR) study, 363–364
National Diabetes Data Group, glucose intolerance definition of, 289, 291
Nephropathy, 316–317
Neuropathy, 317–318
Nitric oxide
  endothelial dysfunction and, 311–312
  insulin resistance and, 311

O
Obesity
  bariatric surgery for, 364
  cardiovascular disease in, 312–313
  cytokines in, cardiovascular disease and, 313
  in pediatric patients, 410
Oral glucose tolerance test (OGTT), in diagnostic criteria, 290–291
Orlistat, for prevention, 364, 389
Oxidative stress, cardiovascular disease and, 315

P
Pediatric patients, 409–417
  cardiovascular risk factors in, 410–412
  diabetes prevention programs for, 364, 414
  metabolic syndrome in, 412–414
  obesity in, 410
Peripheral neuropathy, 317–318
Phenformin, for prevention, 359
Phosphatidylinositol 3-kinase, insulin resistance and, 311
Pioglitazone, for prevention, 362, 388
PIPOD (Pioglitazone In Prevention of Diabetes) study, 362
Positron emission tomography, for glucose uptake, 330
Prediabetes
  definition of, 289–297, 299–303
  diabetes prevention and. See Diabetes mellitus, prevention of.
  diagnosis of, 341–352, 385–386
  epidemiology of, 299–307
  pathophysiology of, 327–339
    beta-cell dysfunction, 332–335
    clinical phenotype and, 335–336
Prediabetes (continued)
   glucose disposal, 330–332
   glucose release, 328–330
   progression to diabetes, 293–294
   risk scores for, 303–304
   screening for, 386–387
   treatment of, 385–395
   vascular complications of, 309–325
Public health implications, of diabetes prevention, 397–407
   evidence for, 398
   four-level model for, 402–404
   global aspect of, 397–398, 400–401
   intervention manager training for, 398–399
   national policy on, 402
   network for, 405
   practical guidance for, 404
   quality indicators for, 399
   target population for, 399, 402
   toolkit for, 404–405

Q
Quality of life, with glucose intolerance and diabetes, 376–377

R
Racial differences, in glycated hemoglobin levels, 302–303
Ramipril, for prevention, 361, 363
Retinopathy, 317
Risk scores, 303–304
Rosiglitazone, for prevention, 363, 388
Rotterdam Predictive Model, 348

S
Sensory neuropathy, 317–318
Study to Prevent Non-Insulin-Dependent Diabetes, 360, 362, 379, 389
Subcutaneous adipose tissue, cardiovascular disease and, 312–313
Swedish Obese Subjects Study, 389

T
Thiazolidinediones, for prevention, 362–363, 388
Thrombosis, cardiovascular disease and, 314–316
Tolbutamide, for prevention, 359
Troglitazone, for prevention, 360, 362–363, 388
TRoglitazone in Prevention of Diabetes (TRIPOD) study, 360, 362, 388
Tumor necrosis factor-α, cardiovascular disease and, 313
U
United Kingdom Prospective Diabetes Study, 354, 376

V
Valsartan, for prevention, 363–364
Visceral adipose tissue
   cardiovascular disease and, 312–313
   in metabolic syndrome, 412–414

W
Whitehall Study, of prevention, 359
World Health Organization
   diabetes mellitus definition of, 289–291
   diabetes risk scores of, 303–304

X
XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study, 364, 389